Reply to M. Rosman et al

Journal of Clinical Oncology

Volumn 28, Issue 31, 2010, Pages

  Dowsett, Mitch ^a   Pineda, Silvia ^b   Cuzick, Jack ^b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TAMOXIFEN;

BREAST CANCER; CANCER RECURRENCE; CANCER RISK; HIGH RISK PATIENT; HUMAN; LETTER; PRIORITY JOURNAL;

EID: 79951908573     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.31.2702     Document Type: Letter

References (2)

1. Rosman M, Mylander WC, Tafra L: What is the value of the 21 gene recurrence score in HER2-negative patients? J Clin Oncol 28:e647, 2010
2. Dowsett M, Cuzick J, Wale C, et al: Prediction of risk of distant recurrence using the 21-gene recurrence score in node- negative and node-positive post-menopausal patients with breast cancer treated with anastrozole or tamoxifen: A TransATAC study. J Clin Oncol 28:1829-1834, 2010